Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $236 | $338 | $317 | $574 |
| - Cash | $67 | $22 | $46 | $64 |
| + Debt | $108 | $106 | $55 | $2 |
| Enterprise Value | $278 | $422 | $325 | $512 |
| Revenue | $31 | $1 | $0 | $0 |
| % Growth | 2,481.5% | 766.2% | -53.4% | – |
| Gross Profit | $30 | -$58 | -$52 | -$55 |
| % Margin | 98% | -4,798% | -37,681.3% | -18,371.8% |
| EBITDA | -$184 | -$170 | -$100 | -$87 |
| % Margin | -592.9% | -14,099.3% | -71,966.2% | -29,126.8% |
| Net Income | -$200 | -$177 | -$102 | -$88 |
| % Margin | -644.8% | -14,710.9% | -73,341% | -29,449% |
| EPS Diluted | -0.63 | -0.8 | -0.62 | -0.61 |
| % Growth | 21.3% | -29% | -1.6% | – |
| Operating Cash Flow | -$179 | -$162 | -$89 | -$87 |
| Capital Expenditures | -$1 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$180 | -$162 | -$90 | -$88 |